sign in sign up
<<
Home , AmFAR, Cancer Institute (WIA), Deborah Anderson, Deborah Birx, Kenneth Cole Productions, Scarlett Johansson

Annual Report 2015 amfAR,The Foundation for AIDS Research Contents

amfAR in 2015 01

Grants, Fellowships, and Awards 07

Research Grants, Fellowships and Awards

TREAT Asia Grants and Awards

GMT Initiative Awards

Public Policy Awards

Financial Highlights 13

Leadership and Advisory Committees 15

Board of Trustees

Scientific Advisory Committee

Program Advisory Council

Management Group

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. amfAR in 2015

Research first three Impact Grants of $2 million each over four years. Countdown to a Cure for AIDS Researchers in Boston, , and Melbourne, In February 2015, amfAR launched a $100 million investment , are investigating the ability of combinations of strategy to support its Countdown to a Cure for AIDS initiative, antibodies to kill latently infected cells, pursuing a novel aimed at developing the scientific basis of a cure by 2020. The intervention aimed at restoring normal immune function in strategy represents an unprecedented expansion of amfAR’s people with HIV, and exploring whether drugs that block so- research grant making. Structured to provide sustained support called immune checkpoints that have proven effective in for a wide range of studies that advance both emerging and treating cancer can also be effective against HIV. established ideas, the strategy comprises the following key ► Investment Grants are aimed at recruiting the experience and components: expertise of scientists from outside the field of HIV. These $1 ► The amfAR Institute for HIV Cure Research, launched at the million grants will be awarded over a four-year period. Grantees end of 2015 at the University of California, San Francisco, will may have expertise in fields such as cancer, neuroscience, or be the cornerstone of amfAR’s cure research efforts and will be inflammatory disease that can directly inform efforts to cure HIV. supported by a $20 million grant over five years. ► ARCHE—the amfAR Research Consortium on HIV Eradication— ► Innovation Grants of up to $200,000 each will enable researchers supports collaborative teams of scientists in the U.S. and around to test innovative ideas supported by limited preliminary data. the world working on a range of HIV cure strategies. In February The first round of 11 Innovation Grants totaling close to $2 million 2015, amfAR awarded $1.5 million to three teams of researchers was awarded in February 2015. in the U.S., Denmark, and Germany who are testing the ability of the cancer drug Romidepsin, which has been shown to be ► Impact Grants support the in-depth development of concepts effective at “shocking” HIV out of hiding, combined with an already underpinned by preliminary data showing genuine antibody to eliminate infected cells and thus reduce the size of potential for achieving a cure. In July, amfAR awarded the the persistent HIV reservoir.

Mathilde Krim Fellowships

In October 2014, amfAR awarded an eighth round of Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results.

Published Research

Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, 44 scientific publications resulted from amfAR-funded research.

HIV Cure Summit

In November 2014, amfAR held its first annual HIV Cure Summit at the Academy of Sciences, where leading amfAR-funded HIV cure researchers reported on their progress and discussed the scientific challenges that continue to stand in the way of a cure. Topics included attempts to eliminate viral reservoirs with methods including “shock and kill,” which involves reactivating the virus so amfAR grantee Dr. Marta Massanella of the University of California, San it can be destroyed; and other immune-based strategies; Diego, is studying a recently discovered subset of CD4 T cells believed to and gene and cell therapy. contribute heavily to the latent HIV reservoir.

1 (Left to right) Panel moderator Dr. Jeffrey Laurence with Drs. Eric Arts of Western University, London, Ontario, Jerome Zack of UCLA, and Lars Østergaard of Aarhus University Hospital, Denmark, at amfAR’s first annual HIV Cure Summit.

Think Tank A Global Collaboration

In March 2015, 12 leading pediatric HIV researchers, immunologists, TREAT Asia manages the Asia-Pacific section of the International and other scientists came together in Las Vegas, Nevada, for a Epidemiologic Databases to Evaluate AIDS (IeDEA), a global second amfAR think tank to discuss progress in the search for a collaboration established by the U.S. National Institute of Allergy cure for children living with HIV. Participants sought to collectively and Infectious Diseases. TREAT Asia is working with the Thai identify new avenues of investigation that can best build upon Red Cross AIDS Research Centre in to conduct a Thai recent breakthroughs. component of a new study that aims to develop and validate a standardized tool to better understand treatment adherence among young people. TREAT Asia amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Improving Care for Children Training in Asia) program is a network of hospitals, clinics, and TREAT Asia’s Pediatric Network includes 18 sites in six countries; research institutions working with civil society to ensure the safe and these sites share information and best practices in an effort to effective delivery of HIV treatments to adults and children across the improve the quality of pediatric care in the region. The TREAT Asia Asia-Pacific through research, education, and advocacy of evidence- Pediatric HIV Observational Database was modeled on the adult based HIV-related policies. The TREAT Asia Network encompasses database and includes data from approximately 5,500 pediatric 20 adult and 18 pediatric sites throughout the region, which patients. collaborate on a variety of projects. TREAT Asia scientists published 28 publications in peer-reviewed medical journals in fiscal year 2015.

Gathering Critical Information

TREAT Asia pioneered the region’s first adult observational database for HIV/AIDS, which now includes anonymous data collected from approximately 9,000 patients at 21 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. In 2015, TREAT Asia launched a new database called TAHOD-Lite that includes more basic data but from a much larger proportion of the HIV-positive patients seen at participating sites.

2 Adolescent Research Youth ACATA (Asia Community for AIDS Treatment and Advocacy) in an effort to mobilize HIV-positive youth across the region. It held In 2015, TREAT Asia conducted several studies aimed at three Youth ACATA workshops for young people living with HIV from improving the health and well-being of adolescents living with , , , and . HIV. Among them was a Thai study, supported by ViiV Healthcare, of whether technology-based interventions can increase adherence to antiretroviral therapy among adolescents. Targeting At-Risk Populations Online In August 2015, Adam’s Love (see Expanding Pre-Exposure Expanding Pre-Exposure Prophylaxis (PrEP) in Thailand Prophylaxis [PrEP] in Thailand) launched Adam’s Love , its fourth country-specific HIV outreach campaign targeting at-risk In an effort to improve national HIV prevention efforts, the populations through its unique online edutainment approach Thai Red Cross AIDS Research Centre, a TREAT Asia network that combines educational HIV resources with videos and social member, and Adam’s Love, Thailand’s leading Internet and social media posts from celebrities. Adam’s Love is supported by media-based HIV outreach initiative, began working on two ViiV and amfAR, and sponsored by the Thai Red Cross AIDS groundbreaking efforts to bring oral PrEP to men who have sex Research Centre. with men (MSM) in Thailand. Both projects are supported in part by TREAT Asia. Education and Advocacy Exploring Links Between HIV and Cancer TREAT Asia continued to publish lay-language articles on AIDS research, policy, and community issues facing the Asia-Pacific Because MSM living with HIV are twice as likely as those without region. The articles and educational pieces appear in the TREAT HIV to develop the anal cancer associated with human papilloma Asia Report, a bimonthly e-newsletter, and on TREAT Asia’s virus (HPV) infection, the Anonymous Clinic of the Thai Red Cross website, www.treatasia.org. TREAT Asia also published a policy AIDS Research Centre started screening its patients for anal brief urging governments, public health authorities, healthcare precancers. With amfAR funding, it purchased the high-resolution providers, and civil society in Asia to address persistent gaps in microscope necessary to diagnose and treat precancerous anal women’s access to reproductive health services, especially for lesions. With support from TREAT Asia and others, three TREAT women living with HIV. Asia sites in Indonesia and have established similar programs. Public Policy Mobilizing HIV-Positive Youth Informed by thorough research and analysis, amfAR is a highly With support from ViiV Healthcare’s new Positive Action for respected advocate of rational and compassionate AIDS-related Adolescents program, TREAT Asia launched a program called public policy. The Foundation works to secure necessary increases

TREAT Asia consultant Jennifer Ho with two Youth ACATA participants at a workshop in Bangkok

3 in funding for HIV/AIDS research; implement the U.S. National HIV/AIDS Strategy; expand access to care and treatment; improve prevention; and protect the civil rights of all people affected by HIV/AIDS.

PEPFAR and the Global Epidemic

PEPFAR—the U.S. President’s Emergency Plan for AIDS Relief— is the largest international program responding to the global HIV/AIDS epidemic and the largest commitment one nation has ever made to combat a disease internationally. In 2015, amfAR launched its PEPFAR Country/Regional Operational Plan database, a comprehensive, navigable database of PEPFAR’s planned funding of HIV/AIDS activities from 2007 to 2014. The database is designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders to access and understand PEPFAR’s programs and priorities at a deeper level than was possible using other platforms. (Left to right) Excellency Jeannette Kagame, First Lady of Rwanda; Dr. Susan Blumenthal, amfAR Senior Policy and Medical Advisor; and Ambassador Deborah Birx, M.D., U.S. Global AIDS Coordinator at an Addressing HIV/AIDS Among Women amfAR-sponsored Congressional briefing. (Photo: amfAR)

In March 2015, amfAR held a Congressional briefing in Washington, D.C., to illuminate the work that remains to be harm reduction programs and syringe exchange in particular. This done to achieve an AIDS-free generation among women and mode of transmission continues to be a driver of the epidemic in girls in the U.S. and globally. The briefing drew leaders from many parts of the world and amfAR has long played a leading role government, academia, and the nonprofit sector, including in advocating the use of federal funds to support these lifesaving House Democratic Leader Nancy Pelosi, Jeannette Kagame, HIV prevention programs. In the wake of the Indiana outbreak, First Lady of Rwanda and cofounder of the Organization of amfAR CEO Kevin Robert Frost authored an op-ed on the issue African First Ladies Against HIV/AIDS, and Ambassador Deborah for CNN.com and amfAR published a pair of issue briefs outlining Birx, M.D., U.S. Global AIDS Coordinator. the importance of syringe services programs (SSPs) as a highly effective tool in the fight against the spread of HIV and hepatitis C.

Shaping the Domestic Response to HIV/AIDS In its Harm Reduction and the Global HIV Epidemic report, released in September 2015, amfAR assessed the state of harm reduction In July 2015, amfAR issued a report titled Bolstering State Efforts worldwide by focusing on the steps that five sample countries— to Implement the National HIV/AIDS Strategy: Key Indicators , Kyrgyzstan, Nigeria, Ukraine, and Vietnam—have, or have and Recommendations for Policymakers and Community not, taken to address the epidemic among people who inject drugs. Stakeholders. The report outlined recommendations for how states across the U.S. can improve their HIV prevention and care responses. It was released to coincide with the White House’s Treatment Access 2015 update to the U.S. National HIV/AIDS Strategy. In a policy brief on hepatitis C and drug pricing, amfAR called for structural changes that alter the pricing incentives for HIV and Black Gay Men pharmaceutical companies in such a way that they cannot charge extortionate prices for their products, however effective they may In February 2015, amfAR published an issue brief showing that be. New pharmaceutical breakthroughs have made curing hepatitis efforts to address the HIV epidemic among black gay men have C infection easier and more effective, but they have been priced at been consistently inadequate and that immediate steps must aggressively high rates that bear no relation to the cost of research be taken to reduce new HIV infections among this underserved and development. population. The brief, titled HIV and the Black Community: Do #Black (Gay) Lives Matter? described the underlying factors In another issue brief titled Trans-Pacific Partnership: Curbing contributing to elevated infection rates among black men Access to Medicines Now and in the Future, amfAR strongly and provided a list of steps that can be taken to mitigate this opposed the proposed terms of the Trans-Pacific Partnership, persistent racial disparity. warning that expanding existing intellectual property protections could result in a decline in generic competition and an increase HIV and Injecting Drug Use in drug costs, while setting an unacceptable precedent for future free trade agreements. Two agreements being negotiated threaten A dramatic spike in HIV infections in rural Scott County, Indiana, the future availability of affordable generic medicines for diseases caused by the sharing of contaminated needles by injecting such as HIV/AIDS, cancer, tuberculosis, and hepatitis C, and could drug users, underscored the urgent need to expand access to undermine the response in developing countries.

4 The GMT Initiative In every corner of the world, gay men, other men who have sex with men, and individuals (collectively, GMT) are disproportionately affected by HIV. Since 2007, amfAR has been advancing efforts to improve prevention for this population, expand access to testing and treatment, and combat stigma and discrimination in hard-hit countries worldwide.

Implementation Science Awards

In 2015, the focus of amfAR’s grant making through the GMT Initiative evolved from the distribution of small grants to community- based organizations to the support of larger implementation science projects aimed at identifying barriers to HIV testing, treatment and care, and studying the impact of innovative HIV service delivery models for GMT in low- The 2015 amfAR HIV Scholars (left to right): Sheryar Kazar, associated with the Naz Male Health and middle-income countries. amfAR awarded Alliance, Pakistan; Liesl Theron, a consultant supported by Gender DynamiX, ; Erika $2.6 million over three years to support three Castellanos from the Collaborative Network of Persons Living with HIV (C-NET+), Belize; and Weibin Cheng from the Chinese Center for Disease Control and Prevention and GZTZ.org. such studies.

► Dr. Chris Beyrer of Johns Hopkins University is leading a team Supporting Young Researchers of researchers and community-based services (in collaboration amfAR also supported four young researchers from Belize, , with the International HIV/AIDS Alliance Myanmar) in evaluating the Pakistan, and South Africa undergoing five months of graduate- effectiveness of promising interventions for GMT in Myanmar, where level public health study at the Center for LGBT Health Research increased HIV testing and treatment opportunities are becoming of the Graduate School of Public Health at the University of available. The researchers are assessing the effectiveness of Pittsburgh. This amfAR HIV Scholars Program aims to strengthen HIV self-testing, point-of-care CD4 testing, and the use of “peer GMT community-based research and responses to HIV, often in navigators” familiar with the local health system to help those areas where little data about HIV among GMT currently exist and newly diagnosed gain access to treatment and care. where stigma and discrimination deter many GMT from seeking HIV testing and services. ► In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud y Educación and his team aim to improve the continuum of care among transgender women by using an innovative model that Opposites Attract integrates HIV prevention and treatment services with transgender- affirming medical care. In January 2015, amfAR provided support to the Instituto Pesquisa Clinica Evandro Chagas in Rio de Janeiro, Brazil, one of 16 clinical ► And in Bangkok, Thailand, Dr. Nittaya Phanuphak and her team sites participating in the Opposites Attract Study, an ongoing at the Thai Red Cross AIDS Research Centre aim to show how international study that explores the effectiveness of “treatment as innovative technologies such as GMT-targeted websites using prevention” in gay male serodiscordant relationships (one sexual online counseling and support can be utilized to increase rates of partner is living with HIV and the other is not). The study aims to HIV testing and referrals to prevention and treatment programs. determine the extent to which HIV incidence is associated with whether an HIV-positive partner is on antiretroviral therapy.

Evidence in Action Lessons from the Front Lines In 2015, amfAR supported five community-based organizations in Africa and Latin America in evaluating their efforts to improve HIV With support from the Arcus Foundation and in collaboration treatment and care among GMT individuals as part of the GMT with Global Action for Trans Equality (GATE), amfAR published Initiative’s Evidence in Action Program, which evaluates the impact Lessons From the Front Lines: Trans Health and Rights. The of community-based programs with the ultimate goal of implementing report examined data on access to health services and legal the most workable strategies for stopping the spread of HIV/AIDS. protections for transgender individuals in different settings Evidence in Action was developed with support from ViiV Healthcare’s and detailed how stigma and discrimination combine to create Positive Action program and the AIDS Foundation. nearly insurmountable challenges for these populations and the organizations that serve them.

5 Public Information Media Outreach Through a wide range of communications vehicles and platforms, amfAR works closely with the media to raise the profi le of HIV/ amfAR disseminates information on important AIDS-related AIDS, both domestically and internationally, and to help ensure research, treatment, prevention, and policy issues for diverse the accuracy of AIDS-related press coverage. Articles and audiences. Through these activities, the Foundation increases reports involving amfAR—many of which included interviews with awareness of the persistent global public health threat posed by amfAR staff and spokespeople—were carried in numerous media HIV/AIDS and works to combat the stigma associated with HIV that outlets, including , , the deters many people from getting tested or seeking treatment. Washington Post, and the Huffi ngton Post, and news agencies such as The Associated Press, CNN, Bloomberg News, and .

Informing and Educating Enlisting the Help of Public Figures amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public fi gures, amfAR’s public awareness efforts are greatly enhanced by the HIV/AIDS scientists, and policymakers in communicating the need committed support of public fi gures who lend their voices and for continued research to develop new methods of prevention, donate their time, talents, and resources to help sustain the treatment, and, ultimately, a cure for AIDS. Publications include Foundation’s mission. Support from prominent public fi gures began Innovations, a newsletter published twice a year and distributed with the late Dame , amfAR’s Founding International to more than 45,000 people, and a monthly e-mail newsletter Chairman, and others have followed in her footsteps. amfAR is distributed to nearly 100,000. Featuring news, interviews, and profoundly grateful for the continuing steadfast support of Global other original content, the Foundation’s website—www..org— Campaign Chair . attracts an average 30,000 visitors per month. Other celebrity supporters included Andrea Bocelli, Adrien Brody, Naomi Campbell, Dean and Dan Caten, , Andy Cohen, Social Media Anderson Cooper, Laverne Cox, Miley Cyrus, Rosario Dawson, Leonardo DiCaprio, , Iman, , amfAR vigorously expanded its presence in the social media amfAR Ambassador Milla Jovovich, Harvey Keitel, , Eva arena, reaching large numbers of people, including a younger Longoria, Lea Michele, Kylie Minogue, Kate Moss, Ryan Murphy, demographic that is often less educated about HIV and the , Eddie Redmayne, , Michelle Rodriguez, AIDS epidemic. The Foundation regularly added content to its Chris Rock, Carine Roitfeld, Brooke Shields, , Robin Facebook page and live-tweeted and posted images on Instagram Thicke, , , Dita Von Teese, Harvey from fundraising and program events. amfAR has 67,000 likes Weinstein, and amfAR Ambassador Michelle Yeoh. on Facebook, 35,400 Twitter followers, and more than 81,000 Instagram followers.

6 2015 RESEARCH GRANTS, The size and maintenance of the latent HIV A3G induced viral evolution reservoir in T-cell subsets Principal Investigator: Spyridon Stavrou, PhD FELLOWSHIPS AND AWARDS Principal Investigator: Marta Massanella, PhD Trustees of the University of Pennsylvania Veterans Medical Research Foundation Philadelphia, PA All projects listed below were awarded San Diego, CA $150,000 Transferred to Université de Montréal, funding during the period October 1, 2014, Montreal, through September 30, 2015 $180,0001 PHASE II KRIM FELLOWSHIP GRANTS Interleukin-21 therapy to reduce HIV persistence 1 Supported in part with funds provided by the Principal Investigator: Mirko Paiardini, PhD Host factors that protect humans and great apes FAIR Foundation Emory University against lentiviruses Atlanta, GA Principal Investigator: Lucie Etienne, PhD amfAR RESEARCH CONSORTIUM ON $179,9991 Institut National de la Santé et de la Recherche HIV ERADICATION (ARCHE) Médicale, INSERM Cell-Intrinsic Immune Modulation of HIV Latency Bron, France Combining romidepsin and 3BNC117 to deplete Principal Investigator: Satish Pillai, PhD $60,000 the HIV-1 reservoir Blood Systems, Inc. Principal Investigator: San Francisco, CA Regulation of Env-specific germinal center B cells Michel Nussenzweig, MD, PhD $180,0001 Principal Investigator: Mattias Forsell, PhD The Rockefeller University, New York, NY Umeå University Co-Investigators: Molecular characterization of non-induced Umeå, Sweden Ole Schmeltz Søgaard, MD, PhD proviruses $56,171 Aarhus University Hospital, Aarhus, Denmark Principal Investigator: Vicente Planelles, PhD Regulation of the conformational transitions in Gerd Fätkenheuer, MD University of Utah HIV-1 envelope glycoprotein University Hospital of Cologne, Cologne, Germany Salt Lake City, UT 1 Principal Investigator: Alon Herschhorn, PhD $1,500,000 $180,000 Dana-Farber Cancer Institute Understanding the role of the HIV Envelope in viral Boston, MA persistence and latency $51,649 INNOVATION GRANTS Principal Investigator: Michael Roche, PhD Peter Doherty Institute Broadly Neutralizing Antibodies for HIV-1 Melbourne, Australia Remission and Eradication $141,719 SCIENTIFIC MEETINGS Principal Investigator: Dan Barouch, MD, PhD Beth Deaconess Medical Center Shaping Innate/Adaptive Immune Effector HIV-1 and How to Kill a Killer: Attempts at Total Boston, MA Functions By TLR9 agonist Immunotherapy Functional Cure of HIV-1 $1,991,958 Principal Investigator: Principal Investigator: Jan Witkowski, PhD Ole Schmeltz Søgaard, MD, PhD Cold Spring Harbor Laboratory Impact of Sirolimus (Rapamycin) on HIV-1 Aarhus University Hospital Cold Spring Habor, NY Persistence and Immune Function Aarhus, Denmark $12,000 Principal Investigator: Timothy Henrich, MD $179,9441 Conference on Cell & Gene Therapy for HIV Cure Regents of the University of California, (2015) San Francisco Impact of everolimus on HIV persistence post Principal Investigator: Keith Jerome, MD, PhD San Francisco, CA kidney or liver transplant Fred Hutchinson Cancer Research Center $2,000,000 An Innovation Grant in Memory of Alberto Diaz Principal Investigator: Peter Stock, MD, PhD Seattle, WA USA $5,000 Combination immune checkpoint blocker Regents of the University of California, San inhibition to eliminate HIV latency Francisco Principal Investigator: Sharon Lewin, FRACP, PhD San Francisco, CA University of Melbourne $180,000 Melbourne, Australia CNS as Reservoir for Subtype C HIV-1 Infection $1,999,740 Principal Investigator: Charles Wood, PhD University of Nebraska-Lincoln Lincoln, NE $180,000 INNOVATION GRANTS

Epigenetic mechanisms of HIV transcriptional activation MATHILDE KRIM FELLOWSHIPS IN Principal Investigator: Karol Bomsztyk, MD BASIC BIOMEDICAL RESEARCH University of Washington Seattle, WA Fc effector activity of anti-HIV-1 broadly $180,000 neutralizing antibodies Principal Investigator: Stylianos Bournazos, PhD Creation of transgenic CCR5 knockout Mauritian The Rockefeller University cynomolgus macaques New York, NY Principal Investigator: Benjamin Burwitz, PhD $150,000 Oregon Health and Science University Portland, OR Activation of the inflammasome by HIV-1 $179,8241 Principal Investigator: Henning Hofmann, PhD New York University Combining CTL with TLR-2 Agonists to Eradicate New York, NY Natural HIV Reservoirs $150,000 Funded with support from generationCURE Principal Investigator: Brad Jones, PhD Decoding the Vpx/Vpr system The George Washington University Principal Investigator: David Schwefel, DSc Washington, DC MRC National Institute for Medical Research $179,985 London, $149,600

7 2015 TREAT ASIA GRANTS St. Vincent’s Hospital Sydney Illawarra Shoalhaven Local Health District Darlinghurst, New South Wales Warrawong, New South Wales AND AWARDS David A. Cooper, MD Katherine Brown, MD $5,2501 $1,350 1Supported by National Institutes of Health Taylor Square Private Clinic University of New South Wales cooperative agreement number U01AI069907 Darlinghurst, New South Wales Sydney, New South Wales with funds from the National Institute of Allergy Robert Finlayson, MBBS Matthew G. Law, PhD and Infectious Diseases, the Eunice Kennedy $5,2501 Asia-Pacific HIV Research Collaboration: TREAT Shriver National Institute of Child Health and Northern Territory Dept of Health & Community Asia HIV Observational Database and Australia Human Development, and the National Cancer Services, Sexual Health & Blood Borne Virus HIV Observational Database Institute Program $361,3141 Darwin, Northern Territory Asia-Pacific HIV Research Collaboration: 2Supported by National Institutes of Health grant Manoji Gunathilake, MD, MBBS, DFSRH $900 Cancer Studies number R01HD073972 funded by the Eunice $60,6861 Kennedy Shriver National Institute of Child Health Gladstone Road Medical Centre Asia-Pacific HIV Research Collaboration: and Human Development. Highgate Hill, Queensland David Orth, MBBS, DIP Ven TREAT Asia Pediatric HIV Observational Database 1 $5,4001 $182,262 3Supported with funds provided by the AIDS Life Association Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic CAMBODIA 4Supported with funds provided by the Open Katoomba, New South Wales Eva Jackson, MBBS, FAChSHM Society Foundations National Center for HIV/AIDS, Dermatology & $1,050 STDS / Cambodia National Institute of Public Health 5Supported with funds provided by ViiV Nepean Blue Mountains Local Health District, Phnom Penh Healthcare Nepean Sexual Health Clinic Kingswood, New South Wales Ly Penh Sun, MD, MSc Eva Jackson, MBBS, FAChSHM TREAT Asia HIV Observational Database (TAHOD) 6 1 Supported with funds provided by the Mel Wolf $750 $20,000 Foundation Sexual Health and AIDS Services (SHAIDS) TREAT Asia Pediatric HIV Observational Database AUSTRALIA Lismore, New South Wales (TApHOD) David Smith, MBBS, DipVen, FAChSHM, $25,0003 AUSTRALIA HIV OBSERVATIONAL DATABASE GrapDip BA 1 National Pediatric Hospital (AHOD) SITES $5,850 Phnom Penh Melbourne Sexual Health Centre Ung Vibol, MD O’Brien Street Practice Clayton, Victoria Training for early disclosure for children and Adelaide, South Australia Tim Read, MBBS, DipVen, FRACGP, FAChSHM, adolescents in National Pediatric Hospital William Donohue, MBBS EpiDip $10,0003 $1,500 $4,6501 New Hope for Cambodian Children Sexual Health and HIV Service In Metro North Victorian HIV Service, Infectious Diseases Killeen, TX Brisbane, Queensland Department, The Alfred Hospital John Tucker Diane Rowling, MBBS, MTH, F(PHM), RACP, Melbourne, Victoria Our Village FAChSHM Jennifer Hoy, MBBS $50,000 $4,6501 $5,9251 Cairns Sexual Health Service Sunshine Coast Hospital and Health Service Cairns, Queensland Nambour West, Queensland CHINA Darren Russell, MD 1 David Sowden, MBBS Beijing Ditan Hospital $4,950 1 $6,750 Beijing RPA Sexual Health Clinic Northside Clinic (Vic) Pty Ltd Fujie Zhang, MD Camperdown, New South Wales North Fitzroy, Victoria TREAT Asia HIV Observational Database (TAHOD) David Templeton, PhD 1 Richard Moore, MBBS, FRACGP, DipOb, DipVen $16,000 $675 1 $7,500 Queen Elizabeth Hospital Monash Health - Clayton Royal Perth Hospital Clayton, Victoria Perth, Western Australia Man Po Lee, MBBS Ian Woolley, MBBS, FRACP David Nolan, MBBS, FRACP, PhD TREAT Asia HIV Observational Database (TAHOD) $3,900 $5,2501 including NCD Data $23,6601 D.A. Ellis Pty., Ltd. Prahran Market Clinic Pty Ltd Coffs Harbour, New South Wales Prahran, Victoria David Ellis, MBBS Norman Roth, MBBS FAChSHM $975 $5,9251 East Sydney Doctors Johns Hopkins University at B.J. Medical College Sydney Sexual Health Centre, Sydney Hospital Darlinghurst, New South Wales and Sassoon General Hospital Sydney, New South Wales David Baker, BHB Pune 1 Caroline Thng, MBBS, MRCP Vidya Mave, MD, MPH $7,050 1 $4,500 Epidemiology of HIV/AIDS and associated Holdsworth House Medical Practice Hunter New England Health, Clinic 468, Tamworth comorbidities in a public antiretroviral treatment Darlinghurst, New South Wales Sexual Health Service (ART) clinic in Pune, India Mark Bloch, MD 1 Tamworth NEMSC, New South Wales $304,185 $6,0001 Nathan Ryder, MD $900

8 Antiviral Research and Treatment Clinical Promoting adherence and nutritional care for Research Site, YRG CARE Medical Centre, VHS Children with HIV Chennai $12,7763 Asian Foundation for Tropical Medicine, Inc. Naglingeswaran Kumarasamy, MBBS, PhD Muntinlupa City TREAT Asia HIV Observational Database (TAHOD) Yayasan Bali Peduli Rossana Ditangco, MD including NCD Data Gianyar, Bali National HIV Testing Week Campaign and $22,8601 Steve Wignall International AIDS Candlelight Memorial, HIV Outreach/Education and Prevention for Youth, Philippines TREAT Asia Pediatric HIV Observational Database Women and Children in Gianyar, Bali $3,351 (TApHOD) $12,0006 $7,5003 TREAT Asia HIV Observational Database (TAHOD) including NCD Data Institute of Infectious Diseases $23,4101 Pune Sanjay Pujari, MD National Center for Global Health and Medicine TREAT Asia HIV Observational Database (TAHOD) Tokyo including NCD Data Shinichi Oka, MD 1 $23,040 TREAT Asia HIV Observational Database (TAHOD) Tan Tock Seng Hospital $16,0001 Singapore Wide Angle Social Development Organization Oon Tek Ng, MBBS, MRC Imphal TREAT Asia HIV Observational Database (TAHOD) Rajkumar Nalinikanta $16,0001 Improving Access to HCV treatment in MALAYSIA Manipur Phase III $8,0874 Hospital Likas Kota Kinabalu Extension of support “Improving Access to HCV Fong Siew Moy, MD treatment” Phase II TREAT Asia Pediatric HIV Observational Database Yonsei University College of Medicine $3,5084 (TApHOD) Seoul $7,5003 Jun Yong Choi, MD, PhD TAHOD Low-Intensity Transfer (TAHOD LITE) Understanding adherence, stigma, and behavioral $5,0001 INDONESIA risk factors of adolescents in TApHOD using ACASI $2,2001 TREAT Asia HIV Observational Database (TAHOD) Cipto Mangunkusumo General Hospital including NCD Data Jakarta Hospital Raja Perempuan Zainab II $18,6901 Nia Kurniati, MD Kota Bharu TREAT Asia Pediatric HIV Observational Database Nik Khairulddin Nik Yusoff, MD (TApHOD) TREAT Asia Pediatric HIV Observational Database 3 TAIWAN $7,500 (TApHOD) 3 Bone health and vitamin D status among perinatally $7,500 Taipei Veterans General Hospital HIV-infected Asian children with virological Taipei City Understanding adherence, stigma, and behavioral Wing-Wai Wong, MD suppression risk factors of adolescents in TApHOD using ACASI 5 $13,065 1 TREAT Asia HIV Observational Database (TAHOD) $2,300 including NCD Data Evy Yunihastuti, MD Pediatric Institute, Hospital Kuala Lumpur $24,5901 TREAT Asia HIV Observational Database (TAHOD) Kuala Lumpur Kaohsiung Medical University including NCD Data Kamarul Azahar Mohd Razali, MD $22,7501 Kaohsiung TREAT Asia Pediatric HIV Observational Database Yi-Ming Chen, MD, ScD Effectiveness and tolerability of HCV treatment (TApHOD) 3 Using the Taiwan National Health Insurance in HIV co-infected patients: Treatment $7,500 Database to Study the Associations between $35,897 Understanding adherence, stigma, and behavioral Chronic Illnesses & Cancer in PLHA $39,3971 Indonesia AIDS Coalition risk factors of adolescents in TApHOD using ACASI 1 Jakarta $4,200 Aditya Wardhana Penang Hospital THAILAND Creating joint action plans to address the needs Georgetown of Children Living with HIV Revathy Nallusamy, MBBS 5 Chiang Mai University - Research Institute for $9,047 TREAT Asia Pediatric HIV Observational Database Health Sciences Sanglah Hospital, Udayana University School (TApHOD) Chiang Mai 3 of Medicine $2,500 Romanee Chaiwarith, MD TREAT Asia HIV Observational Database (TAHOD) Denpasar, Bali Sungai Buloh Hospital Tuti Parwati Merati, MD including NCD Data Sungai Buloh $25,2401 TREAT Asia HIV Observational Database Benedict Lim Heng Sim, MBBS, MRCP (TAHOD) including NCD Data TREAT Asia HIV Observational Database (TAHOD) 1 Tavitiya Sudjaritruk, MD, ScM $23,00 $15,0001 TREAT Asia Pediatric HIV Observational Database Sanglah Hospital, Udayana University School (TApHOD) University of Malaya $15,0003 of Medicine Kuala Lumpur Denpasar, Bali Adeeba Kamarulzaman, MBBS, FRACP, FAMM, Bone health and vitamin D status among Ketut Dewi Kumara Wati, MD FASc perinatally HIV-infected Asian children with TREAT Asia Pediatric HIV Observational TREAT Asia HIV Observational Database (TAHOD) virological suppression Database (TApHOD) including NCD Data 5 3 $72,092 $7,500 $23,0001 Chiangrai Prachanukroh Hospital Spiritia Foundation Effectiveness and tolerability of HCV treatment in Chiang Rai Jakarta HIV co-infected patients: Treatment Rawiwan Hansudewechakul, MD Meirinda Sebayang $20,195 TREAT Asia Pediatric HIV Observational Indonesia pediatric HIV program assessment 5 Database (TApHOD) $9,986 $15,0003

9 Understanding adherence, stigma, and behavioral Study Site: Human Papillomavirus Infection in Understanding adherence, stigma, and risk factors of adolescents in TApHOD using Perinatally HIV-infected Adolescents in Asia behavioral risk factors of adolescents in TApHOD ACASI $80,2232 using ACASI $4,6501 $8,5001 Coordinating Center: Prospective Monitoring of Human Papillomavirus Infection in Perinatally Second-line Antiretroviral Therapy Failure and TASER-Px: Prospective Monitoring of HIV-infected Adolescents in Asia Resistance in Children Second-line Antiretroviral Therapy Failure $63,6132 $46,4671 and Resistance in Children $14,0003 Pacharee Kantipong, MD TASER-Px: Prospective Monitoring of TREAT Asia HIV Observational Database (TAHOD) Second-line Antiretroviral Therapy Failure Thoa Kim Le Phan, MD including NCD Data and Resistance in Children Human Papillomavirus Infection in Perinatally $15,4601 $13,0005 HIV-infected Adolescents in Asia $9,5482 HIV-NAT / Thai Red Cross AIDS Research Centre Kiat Ruxrungtham, MD Bangkok Effectiveness and tolerability of HCV treatment in Children’s Hospital 2 Praphan Phanuphak, MD, PhD HIV co-infected patients: Treatment Ho Chi Minh City TREAT Asia HIV Observational Database (TAHOD) $48,412 Do Chau Viet, MD including NCD Data TREAT Asia Pediatric HIV Observational Database $22,8901 Thai Red Cross AIDS Research Centre (TApHOD) Bangkok $20,0003 Examining the prevalence rate and determinants Nittaya Phanuphak, MD, PhD of frailty in the HIV positive and negative Thai Strengthening skills and qualifications of HRA TASER-Px: Prospective Monitoring of Second-line populations clinicians in the Asia-Pacific region Antiretroviral Therapy Failure and Resistance in $30,8731 $42,600 Children $20,0003 Torsak Bunupuradah, MD eHealth interventions to improve treatment TREAT Asia Pediatric HIV Observational Database adherence and retention in care among HIV- Hung Vuong Hospital (TApHOD) positive young Thai MSM Ho Chi Minh City $15,0001 $44,9935 Dang Le Dung Hanh, MD, MA Human Papillomavirus Infection in Perinatally HIV- Bone health and vitamin D status among Mahidol University Faculty of Medicine, infected Adolescents in Asia perinatally HIV-infected Asian children with Siriraj Hospital $15,5982 virological suppression Bangkok $110,2825 Kulkanya Chokephaibulkit, MD National Hospital of Pediatrics TREAT Asia Pediatric HIV Observational Database Hanoi Changes in metabolic and inflammatory markers (TApHOD) Nguyen Van Lam, MD, MSc in HIV-positive adolescents using hormonal $15,0003 TREAT Asia Pediatric HIV Observational Database contraception (TApHOD) 3 $10,350 Understanding adherence, stigma, and behavioral $20,0003 risk factors of adolescents in TApHOD using Promoting Mental Health Interventions for ACASI Understanding adherence, stigma, and behavioral Perinatally HIV-Infected Thai Youth: Expanded $7,2361 risk factors of adolescents in TApHOD using Scope ACASI 3 $6,500 Human Papillomavirus Infection in Perinatally HIV- $4,2001 infected Adolescents in Asia Stephen Kerr, PhD $66,2162 TASER-Px: Prospective Monitoring of Second-line Prospective validation of an adherence monitoring Antiretroviral Therapy Failure and Resistance in tool among HIV-infected children and adolescents Ramathibodi Hospital, Mahidol University Children at IeDEA sites Bangkok $8,5003 $10,8141 Sasisopin Kiertiburanakul, MD, MHS TREAT Asia HIV Observational Database (TAHOD) National Hospital of Tropical Diseases Nittaya Phanuphak, MD, PhD including NCD Data Hanoi Identifying Biomarkers of Anal Intraepithelial $23,8801 Nguyen Van Kinh, MD, PhD Neoplasia in Thai MSM TREAT Asia HIV Observational Database (TAHOD) 1 $95,000 Srinagarind Hospital, Khon Kaen University including NCD Data Khon Kaen $23,2301 Study on anal HPV infection and anal intraepithelial Pagakrong Lumbiganon, MD neoplasia among MSM in Indonesia, Malaysia, and TREAT Asia Pediatric HIV Observational Database Effectiveness and tolerability of HCV treatment in Thailand (TApHOD) HIV co-infected patients: Treatment 1 3 $34,646 $172,602 $15,0003 $32,065 Human Papillomavirus Infection in Perinatally Understanding adherence, stigma, and behavioral Vietnam Network of People Living with HIV (VNP+) HIV-infected Adolescents in Asia (central lab & risk factors of adolescents in TApHOD using Hanoi data manager) ACASI Do Dang Dong 2 $249,357 $5,1501 Strengthen advocacy on HCV Diagnosis, Care and HIV-HPV Research in Asia and the Pacific Meeting Treatment 4 $20,6191 $2,000 VIETNAM Wasana Prasitsuebsai, MD, MPH Understanding adherence, stigma, and behavioral Bach Mai Hospital risk factors of adolescents in TApHOD using Hanoi ACASI Pham Thi Thanh Thuy, MD, PhD $5,7751 TREAT Asia HIV Observational Database (TAHOD) including NCD Data Understanding adherence, stigma, and behavioral $23,0701 risk factors of adolescents in TApHOD using ACASI (data mgmt center) Children’s Hospital 1 $8,0001 Ho Chi Minh City Truong Huu Khanh, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) $25,0003

10 2015 GMT INITIATIVE Opposites Attract Study Site 2015 COMMUNITY Site Principal Investigator: GRANTS AND AWARDS Beatriz Grinsztejn, MD, PhD OUTREACH AWARDS Fiotec - Foundation for Scientific and All projects listed below were awarded Technological Development in Health, Instituto de Pesquisa Clinica Evandro Chagas Andrea Bocelli Foundation-St. Damien amfAR funding for the period October 1, Rio de Janeiro, Brazil Pediatric Hospital, Haiti 2014, through September 30, 2015. $96,398 Charities Aid Foundation of America Alexandria, VA USA A Training Program for HIV Research among $301,163 MSM in Developing World Settings GMT IMPLEMENTATION SCIENCE Project Director: Ronald D. Stall, PhD, MPH The Learning Resource RESEARCH GRANTS University of Pittsburgh Museum of AIDS in Africa Pittsburgh, PA Johannesburg, Gauteng South Africa $163,804 $25,000 Continuum of Care Innovations for GMT in Burma/Myanmar Principal Investigator: Chris Beyrer, MD, MPH Johns Hopkins University 2015 PUBLIC POLICY Baltimore, MD $899,887 AWARDS

Gender-Affirmative Transgender Care to Improve The projects listed below were awarded the HIV Treatment Cascade Principal Investigator: Javier Lama, MD, MPH during the period October 1, 2014, through Asociación Civil Impacta Salud y Educación September 30, 2015. Lima, Peru $876,684 1Funded with support from the Open Society Foundations Innovative strategy to offer online Test and Treat services for Thai MSM 2Funded with support from the MAC AIDS Fund Principal Investigator: Nittaya Phanuphak, MD, PhD Thai Red Cross AIDS Research Centre Bangkok, Thailand $900,000 Implementation of Electronic Medical Record System Project Director: Ron Simmons, PhD GLOBAL LUBRICANT ACCESS Us Helping Us - People Into Living, Inc. MOBILIZATION AWARDS Washington, DC GLAM: CNET $4,875 Project Director: Stephen Diaz Harm Reduction Services and Overdose Collaborative Network of Persons Living with HIV Prevention Advocacy in Puerto Rico (C-NET+) Project Director: Rafael Torruella, PhD Belize City, Belize Intercambios Puerto Rico $5,000 Fajardo, Puerto Rico 1 GLAM: ALFIL $20,000 Project Director: Ricardo Erazo Asociación ALFIL Quito, Ecuador INTERNATIONAL $5,000 Meaningful Engagement of People who Use GLAM: Groupo Genesis Panama Positivo Drugs (PUD) in Removing Legal Barriers towards Project Director: Israel Ned Gill Smith access to antiretroviral treatment Grupo Génesis Panamá Positivo (GGP+) Project Director: Edo Agustian Panamá, Panamá Persaudaraan Korban Napza Indonesia (PKNI) $5,000 Jakarta, Indonesia $20,0001 GLAM: Red Trebol Project Director: Pamela Valenzuela Advocating for Human rights and access to health Mesa De Trabajo Nacional services for People Who Use Drugs (PWUD) Cochabamba, Bolivia Project Director: Happy Leonard Assan $5,000 Tanzania network for people who use drugs Dar-es-salaam, Tanzania $10,0001 GENERAL GMT INITIATIVE GRANTS AND Project ACE AWARDS Project Director: Shaun Shelly Opposites Attract Study (Extension) TB/HIV Care Association Cape Town, South Africa Principal Investigator: Andrew Grulich, PhD, 1 FAFPM, DRACOG $19,466 University of New South Wales Qualitative Assessment of Budget Development Sydney, Australia and the Improvement of Health Outcomes $212,340 Project Director: Nhlanhla Ndlovu Centre for Economic Governance and AIDS in Africa Howick, South Africa $39,9452

11 12 Financial Highlights For the year ended September 30, 2015

Public Support and Revenue Public support $ 7,142,007 Special events 24,033,779 Planned giving 5,095,713 Government funding 10,220,999 Investment income and other revenue 117,700 Total public support and revenue $ 46,610,198

Expenses Research $ 15,282,648 TREAT Asia 5,820,593 GMT Initiative 2,365,247 Public Policy 2,045,870 Public Information 4,259,732 Total program services $ 29,774,090

Fundraising 5,653,227 Management and general 2,454,606 Total supporting services $ 8,107,833

Total expenses $ 37,881,923

Change in net assets 8,728,275 Net assets, beginning of year 44,310,347

Net assets, end of year $ 53,038,622

Statement of Financial Position

Assets Cash and investments $ 58,377,633 Accounts receivable, net 7,557,420 Prepaid expenses and other assets 3,027,106 Fixed assets, net 2,288,934 Total Assets $ 71,251,093

Liabilities Accounts payable and accrued expenses $ 3,435,700 Grants and fellowships payable, net 3,049,552 Deferred support and refundable advances 10,067,061 Other long-term liabilities 1,660,158 Total liabilities $ 18,212,471

Total net assets 53,038,622

Total liabilities and net assets $ 71,251,093

13 Expenses

Fundraising $ 5,653,227 Management and general 2,454,606 Program 29,774,090

Total $ 37,881,923

Program Expenses

Research $ 15,282,648 TREAT Asia 5,820,593 GMT Initiative 2,365,247 Public Policy 2,045,870 Public Information 4,259,732

Total $ 29,774,090

14 T. Ryan Greenawalt IN MEMORIAM BOARD OF TRUSTEES Managing Director Fiscal year 2015 Ramirez & Co. Dame Elizabeth Taylor President Founding International Chairman Chairman of the Board Harrison Street Productions New York, NY Sheldon W. Andelson, Esq. Chairman Arnold W. Klein, M.D. Regan Hofmann Kenneth Cole Productions Mrs. Albert D. Lasker Policy Officer New York, NY Jonathan M. Mann, M.D., M.P.H. Washington Liaison Office Maxine Mesinger Founding Chairman UNAIDS Pauline Phillips Mathilde Krim, Ph.D. Washington, D.C. Natasha Richardson Adjunct Professor Allan Rosenfield, M.D. Michael J. Klingensmith Mailman School of Public Health Peter Scott, Esq. CEO and Publisher Columbia University Tom Stoddard Minneapolis Star Tribune New York, NY Joel D. Weisman, D.O. Minneapolis, MN Vice Chairman Kevin McClatchy Patricia J. Matson Chairman of the Board Senior Vice President, Communications (ret.) SPECIAL APPOINTMENTS The McClatchy Company ABC, Inc. Ligonier, PA New York, NY Global Campaign Chair Michele V. McNeill, Pharm.D. Sharon Stone Vice Chairman Chairman John C. Simons Global Fundraising Chairman McNeill Family Foundation Managing Partner Milutin Gatsby Sarasota, FL Corporate Fuel Partners, LLC New York, NY Edward L. Milstein Co-Chairman Treasurer amfAR AMBASSADORS Milstein Brothers and Capital Partners Wallace Sheft, C.P.A. New York, NY Partner (ret.) Cheyenne Jackson Janet Jackson Sheft & Co. Cindy D. Rachofsky Westbury, NY Milla Jovovich Philanthropist Dallas, TX Secretary Michelle Yeoh Mervyn F. Silverman, M.D., M.P.H. Vincent A. Roberti President Chairman, Roberti Global Mervyn F. Silverman Associates Washington, D.C. Crockett, CA COMMITTEES OF THE BOARD Bill Roedy OF TRUSTEES London, UK TRUSTEES Raymond F. Schinazi, Ph.D., D.Sc. Executive Frances Winship Walters Professor Kenneth Cole, Chair Arlen H. Andelson Director, Laboratory of Biochemical Pharmacology Michael J. Klingensmith Andelson Properties Emory University Mathilde Krim, Ph.D. , CA Decatur, GA Patricia J. Matson Vincent A. Roberti Alan D. Schwartz Wallace Sheft, C.P.A. President Executive Chairman Mervyn F. Silverman, M.D., M.P.H. Belafonte Enterprises, Inc. Guggenheim Partners, LLC John C. Simons New York, NY New York, NY Audit David Bohnett Diana L. Taylor Wallace Sheft, C.P.A., Chair Chairman Vice Chair R. Martin Chavez, Ph.D. David Bohnett Foundation Solera Capital, LLC John C. Simons Beverly Hills, CA New York, NY Board Development Zev Braun Donald A. Capoccia, Co-Chair President and CEO Patricia J. Matson, Co-Chair Braun Entertainment Group, Inc. TRUSTEE EMERITUS Arlen Andelson Beverly Hills, CA Bill Roedy Arthur J. Ammann, M.D. Mervyn F. Silverman, M.D., M.P.H. Jonathan S. Canno President, Global Strategies for HIV Prevention New York, NY Clinical Professor of Pediatrics Communications/Social Media/Marketing University of California, San Francisco Regan Hofmann, Chair Donald A. Capoccia San Francisco, CA Kenneth Cole Managing Principal T. Ryan Greenawalt BFC Partners Patricia J. Matson Brooklyn, NY Kevin McClatchy Vincent A. Roberti R. Martin Chavez, Ph.D. Bill Roedy Chief Information Officer The Goldman Sachs Group, Inc. Compensation and Organizational Development New York, NY John C. Simons, Chair Michael J. Klingensmith Jane B. Eisner Kevin McClatchy President The Eisner Foundation Bel Air, CA

15 Finance & Budget Dennis R. Burton, Ph.D. Roger Detels, M.D., M.S. Michael J. Klingensmith, Chair Professor Professor of Epidemiology Vincent A. Roberti Department of School of Public Health John C. Simons The Scripps Research Institute University of California, Los Angeles

Fund Development Salvatore T. Butera, D.V.M., Ph.D. Carl W. Dieffenbach, Ph.D. Vincent A. Roberti, Chair Chief Science Officer Director Arlen Andelson Scripps CHAVI-ID Division of AIDS (DAIDS) Jonathan S. Canno The Scripps Research Institute National Institute of Allergy and Infectious Donald A. Capoccia Diseases T. Ryan Greenawalt Edward Campbell, Ph.D. National Institutes of Health Cindy Rachofsky Assistant Professor Raymond F. Schinazi, Ph.D., D.Sc. Department of Microbiology and Immunology D. Peter Drotman, M.D., M.P.H. School of Medicine Editor in-Chief Investment Loyola University at Chicago Emerging Infectious Diseases Michael J. Klingensmith, Chair Centers for Disease Control and Prevention R. Martin Chavez, Ph.D. Alex Carballo-Dieguez, Ph.D. Edward L. Milstein Co-Director and Senior Research Scientist Anke A. Ehrhardt, Ph.D. Vincent A. Roberti HIV Center for Clinical and Behavioral Studies Director Wallace Sheft, C.P.A. New York State Psychiatric Institute Division of Gender, Sexuality, & Health John C. Simons Columbia University Program for the Study of LGBT Health NYS Psychiatric Institute/Columbia University Nicolas Chomont, Ph.D. Assistant Professor Jacob Estes, Ph.D. Microbiology and Immunology Principal Scientist/Principal Investigator SCIENTIFIC ADVISORY Université de Montréal, Centre de Recherche du AIDS and Cancer Virus Program (ACVP) COMMITTEE CHUM Frederick National Laboratory for Cancer Research National Cancer Institute David B. Clifford, M.D. Professor Homayoon Farzadegan, Ph.D. Daniel C. Douek, M.D., Ph.D. (Chair) Department of Neurology Professor Chief, Human Immunology Section Washington University School of Medicine Department of Epidemiology Research Center Johns Hopkins Bloomberg School of Public Health National Institute of Allergy and Infectious C. Budd Colby, Ph.D. Diseases Principal Dianne M. Finkelstein, Ph.D. National Institutes of Health Colby Biomedical Ventures Professor of Biostatistics Harvard School of Public Health Galit Alter, Ph.D. Grant Colfax, M.D. Director of the Cancer Center Biostatics Associate Professor Director Massachusetts General Hospital Department of Medicine Marin Health and Human Services Harvard Medical School San Rafael, California Gerald Herbert Friedland, M.D. Professor and Director Deborah Anderson, Ph.D. Elizabeth Connick, M.D. AIDS Care Program Professor of Obstetrics/Gynecology Professor of Medicine Department of and Microbiology Chief, Division of Infectious Diseases Yale School of Medicine Boston University School of Medicine Department of Medicine University of Arizona Rémi Fromentin, Pharm.D., Ph.D. Jintanat Ananworanich, M.D., Ph.D. Postdoctoral Researcher Associate Director for Therapeutics Research Deborah Jean Cotton, M.D., M.P.H. Université de Montréal, Centre de Recherche du U.S. Military HIV Research Program Professor of Medicine CHUM Boston University School of Medicine Warren A. Andiman, M.D. Howard E. Gendelman, M.D. Professor Emeritus of Pediatrics Bryan R. Cullen, Ph.D., D.Sc. Professor and Chair, Department of Pharmacology Co-Director, Yale Adoption Clinic James B. Duke Professor and Experimental Neuroscience Medical Director, Pediatric AIDS Care Program Department of Molecular Genetics and Margaret R. Larson Professor of Internal Medicine Yale School of Medicine Microbiology and Infectious Diseases Director, Duke University Center for Virology Director, Center for Neurodegenerative Disorders Eric Arts, Ph.D. Duke University Medical Center University of Nebraska Medical Center Professor Department of Microbiology and Immunology Susanna Cunningham-Rundles, Ph.D. Nancy L. Haigwood, Ph.D. The University of Western Ontario Professor Emerita of Research Immunology Director and Senior Scientist Department of Pediatrics Division of Pathobiology and Immunology Livio Azzoni, Ph.D. Weill Cornell Medical College Oregon National Primate Research Center Senior Staff Scientist Oregon Health and Science University The Wistar Institute Richard Thomas D’Aquila, M.D. Philadelphia, PA The Howard Taylor Ricketts Professor of Medicine Timothy Henrich, M.D. Division of Infectious Diseases Assistant Professor of Medicine Michael Betts, Ph.D. Director, Northwestern HIV Translational Division of Infectious Disease Associate Professor Research Center University of California, San Francisco Department of Microbiology Feinberg School of Medicine Perelman School of Medicine Northwestern University Charles H. Hinkin, Ph.D. University of Pennsylvania Professor Steven Deeks, M.D. Department of Psychiatry and Biobehavioral Jason Brenchley, Ph.D. Professor Sciences Senior Investigator Department of Medicine David Geffen School of Medicine Immunopathogenesis Section University of California, San Francisco Univerity of California, Los Angeles National Institute of Allergy and Infectious Diseases Sherry Deren, Ph.D. David Ho, M.D. National Institutes of Health Co-Director Scientific Director, Chief Executive Officer Center for Drug Use and HIV Research Aaron Diamond AIDS Research Center New York University College of Nursing 16 Thomas J. Hope, Ph.D. Sharon Lewin, FRACP, Ph.D. Savita Pahwa, M.D. Professor Director Professor of Microbiology and Immunology Department of Cell and Molecular Biology Peter Doherty Institute for Infection and Immunity Professor in Pediatrics and Medicine Feinberg School of Medicine University of Melbourne Director of the Miami Center for AIDS Research Northwestern University University of Miami Leonard M. Miller School of Mathias Lichterfeld, M.D. Medicine Shiu-Lok Hu, Ph.D. Assistant Professor of Medicine Professor Massachusetts General Hospital Tristram G. Parslow, M.D., Ph.D. School of Pharmacy William Patterson Timmie Professor and Chair University of Washington Judy Lieberman, M.D., Ph.D. Department of Pathology and Laboratory Medicine Senior Investigator Emory University School of Medicine Jonathan Karn, Ph.D. Immune Disease Institute Director Professor of Pediatrics Matija Peterlin, M.D. Center for AIDS Research Harvard Medical School Professor of Medicine, Microbiology and Case Western Reserve University Immunology H. Kim Lyerly, M.D. Department of Medicine Vineet KewalRamani, Ph.D. Professor in Surgery, Immunology, Pathology University of California, San Francisco Chief, Model Development Section George Barth Geller Chair of Cancer Research HIV Drug Resistance Program Director of the Center of Applied Therapeutics Lynn Pulliam, Ph.D. National Cancer Institute Duke Cancer Institute Professor National Institutes of Health Duke University Medical Center Department of Laboratory Medicine and Medicine University of California, San Francisco Hans-Peter Kiem, M.D., F.A.C.P. Frank Maldarelli, M.D., Ph.D. Veterans Affairs Medical Center Full Member, Clinical Research Division Investigator Jose Carreras/E. Donnall Thomas Endowed HIV DRP Host-Virus Interaction Branch Lee Ratner, M.D., Ph.D. Chair for Cancer Research National Cancer Institute Professor Fred Hutchinson Cancer Research Center National Institutes of Health Department of Medicine Seattle, WA Washington University School of Medicine David M. Margolis, M.D. Scott Kitchen, Ph.D. Professor of Medicine, Microbiology and Andrew Rice, Ph.D. Assistant Professor of Medicine Immunology, and Epidemiology Professor Division of Hematology and Oncology School of Medicine Department of Molecular Virology and David Geffen School of Medicine University of North Carolina at Chapel Hill Microbiology University of California, Los Angeles Baylor College of Medicine Martin H. Markowitz, M.D. Richard Kornbluth, M.D., Ph.D. Professor and Clinical Director Charles Rinaldo, Ph.D. President and Chief Scientific Officer Aaron Diamond AIDS Research Center Professor and Chair Multimeric Biotherapeutics, Inc. Infectious Diseases and Microbiology Kenneth Hugh Mayer, M.D. University of Pittsburgh Richard A. Koup, M.D. Infectious Disease Attending & Director of HIV Deputy Director, Vaccine Research Center Prevention Research Melissa Robbiani, Ph.D. Chief, Immunology Laboratory Beth Israel Deaconess Medical Center Senior Scientist and Director of Biomedical HIV National Institute of Allergy and Infectious Research Diseases Professor of Medicine Center for Biomedical Research National Institutes of Health Harvard Medical School Population Council

Nathaniel R. Landau, Ph.D. Medical Research Director, Co-Chair Ruth M. Ruprecht, M.D., Ph.D. Professor The Fenway Institute/Fenway Health Scientist, Department of Virology and Immunology Department of Microbiology Southwest National Primate Research Center New York University School of Medicine Joseph M. McCune, M.D., Ph.D. Director, Texas Biomed AIDS Research Program Professor of Medicine Texas Biomedical Research Institute Alan L. Landay, Ph.D. Chief, Division of Experimental Medicine Professor and Chairman University of California, San Francisco Sarah Schlesinger, M.D. Department of Immunology and Microbiology Associate Professor of Clinical Investigation Rush-Presbyterian-St. Luke’s Medical Center Donna Mildvan, M.D. Laboratory of Molecular Immunology Chief, Division of Infectious Diseases The Rockefeller University Michael Lederman, M.D. Department of Medicine Scott R. Inkley Professor of Medicine Beth Israel Medical Center Frederick A. Schmitt, Ph.D. Associate Director, Center for AIDS Research Professor Case Western Reserve University Jay A. Nelson, Ph.D. Departments of Neurology, Psychiatry, and Professor and Director Psychology and Behavioral Science Tun-Hou Lee, D.Sc. Vaccine and Gene Therapy Institute Sanders Brown Center on Aging Professor of Virology, Emeritus Oregon Health and Science University University of Kentucky Department of Immunology and Infectious Diseases Una O’Doherty, M.D., Ph.D. Gerald Schochetman, Ph.D. Harvard School of Public Health Associate Professor Senior Director, Diagnostics Research Department of Pathology and Laboratory Medicine Abbott Laboratories Michael J. Leibowitz, M.D., Ph.D. Perelman School of Medicine Professor, Medical Microbiology and Immunology University of Pennsylvania Robert Turner Schooley, M.D. University of California, Davis Academic Vice Chair Nancy Padian, Ph.D., M.P.H. Professor and Head Robert J. Levine, M.D. Adjunct Professor of Epidemiology Department of Medicine/Division of Infectious Professor of Medicine School of Public Health Diseases Center for Interdisciplinary Research on AIDS University of California, Berkeley University of California, San Diego Yale University

17 Gail Skowron, M.D. PROGRAM ADVISORY MANAGEMENT GROUP Professor of Medicine Boston University School of Medicine COUNCIL

Serena Spudich, M.D., M.A. Mervyn F. Silverman, M.D., M.P.H. (Chairman) Kevin Robert Frost Associate Professor of Neurology President Chief Executive Officer Division Chief, Neurological Infections Mervyn F. Silverman Associates and Global Neurology Crockett, CA Anthony Ancona Department of Neurology Vice President and Director, Human Resources Yale School of Medicine Judith D. Auerbach, Ph.D. Science and Policy Consultant and Professor Susan J. Blumenthal, M.D., M.P.A. Leonidas Stamatatos, Ph.D. School of Medicine Senior Policy and Medical Advisor Member University of California, San Francisco Bradley Jensen Fred Hutchinson Cancer Research Center Chief Financial Officer Vaccine and Infectious Disease Division David Bloom, Ph.D. Immunology and Vaccine Development Program Clarence James Gamble Professor of Economics Rowena Johnston, Ph.D. Seattle, WA and Demography Vice President and Director, Research Department of Global Health and Population Mario Stevenson, Ph.D. Harvard School of Public Health Jeffrey Laurence, M.D. Professor of Medicine Boston, MA Senior Scientific Consultant for Programs Chief, Division of Infectious Diseases University of Miami Leonard M. Miller School Tim Brown, Ph.D. John F. Logan, Ph.D., J.D. of Medicine Senior Fellow Vice President and General Counsel The East-West Center Honolulu, HI Gregorio Millett, M.P.H. Susana Valente, Ph.D. Vice President and Director, Public Policy Associate Professor Daniel Douek, M.D., Ph.D. Department of Immunology and Microbial Chief, Human Immunology Section Eric Muscatell Sciences Vaccine Research Center Vice President, Development The Scripps Research Institute National Institute of Allergy and Infectious AnnMari Shannahan Diseases Barbara Visscher, M.D., Dr.P.H. Vice President, Public Information National Institutes of Health Professor of Epidemiology Annette Sohn, M.D. University of California, Los Angeles Daria J. Hazuda, Ph.D. Vice President and Director, TREAT Asia Vice President, Scientific Affairs for Infectious David Vlahov PhD, RN Disease Professor of Nursing, Merck & Company, Inc. Epidemiology, and Biostatistics West Point, PA University of California, San Francisco Kenneth Hugh Mayer, M.D. David J. Volsky, Ph.D. Infectious Disease Attending & Director of HIV Professor of Medicine and Pathology Prevention Research Icahn School of Medicine at Mt. Sinai Beth Israel Deaconess Medical Center Director of Molecular Virology Laboratory Professor of Medicine Department of Medicine Harvard Medical School Mount Sinai St. Luke’s and Roosevelt Hospitals Medical Research Director, Co-Chair Steven S. Witkin, Ph.D. The Fenway Institute/Fenway Health Professor of Immunology Mario Stevenson, Ph.D. Department of Obstetrics and Gynecology Professor of Medicine Weill Cornell Medical College Chief, Division of Infectious Diseases Peter R. Wolfe, M.D. University of Miami Leonard M. Miller School of Associate Clinical Professor Medicine David Geffen School of Medicine Jeffrey L. Sturchio, Ph.D. University of California, Los Angeles Senior Partner Rabin Martin Steven Wolinsky, M.D. New York, NY Professor Medicine/Infectious Diseases Visiting Scholar Feinberg School of Medicine The Institute for Applied Economics, Global Health Northwestern University and the Study of Business Enterprise Johns Hopkins University Richard T. Wyatt, Ph.D. Professor of Immunology Member IAVI Center for Neutralizing Antibodies The Council on Foreign Relations The Scripps Research Institute Washington, D.C.

Jerome Zack, Ph.D. Phill Wilson Professor Chief Executive Officer and President Department of Medicine The Black AIDS Institute David Geffen School of Medicine Los Angeles, CA University of California, Los Angeles

18 amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1100 Vermont Avenue, NW Suite 600 Washington, DC 20005 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (tel) +66 (0)2 663 7562 (fax) www.amfar.org

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability.